Epirubicin
Ovarian Clear Cell Tumor
HonorHealth Research InstitutePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Ovarian Clear Cell Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Barbara Ann Karmanos Cancer Institute | Phase 1 | CC |
Valproic Acid Barbara Ann Karmanos Cancer Institute | Phase 1 | CC |
Cyclophosphamide HonorHealth Research Institute | Phase 1 | CC |
nxp800 Nuvectis Pharma, Inc. | Phase 1 | CC |
Pembrolizumab HonorHealth Research Institute | Phase 1 | CC |
Seclidemstat HonorHealth Research Institute | Phase 1 | CC |
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →